Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ketamine + morphine is a combination of two analgesic drugs used together primarily for the management of moderate to severe pain, especially in perioperative, emergency, and chronic pain settings. Ketamine is a rapid-acting dissociative anesthetic and N-methyl-D-aspartate (NMDA) receptor antagonist that provides analgesia by inhibiting excitatory neurotransmission involved in pain pathways. Morphine is an opioid agonist that acts mainly on mu-opioid receptors to produce potent analgesia. When combined, ketamine and morphine have been shown to provide synergistic or additive effects on pain relief, potentially reducing opioid requirements and attenuating the development of opioid tolerance. This combination may also be used when single-agent therapy is insufficient or when minimizing opioid dosage is desired due to side effect profiles[2][4][10].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ketamine + morphine.